IBM Watson Health, Cambridge, MA (Dr Henke, Ellsworth, Wier, Snowdon); and CVS Health, Rhode Island, Woonsocket (Dr Wier).
J Occup Environ Med. 2020 May;62(5):344-349. doi: 10.1097/JOM.0000000000001830.
To measure the prevalence of opioid use disorder (OUD) and employee health care and productivity costs with and without OUD and to assess whether utilization of pharmacotherapy for OUD reduces those costs.
We conducted a cross-sectional analysis of 2016 to 2017 commercial enrollment, health care, and pharmacy claims and health risk assessment data using the IBM MarketScan Databases (Ann Arbor, MI). We estimated regression models to assess the association between OUD and annual employee health care and productivity costs.
Health care and productivity costs for employees with OUD who did and did not receive pharmacotherapy were approximately $6294 and $21,570 more than for other employees, respectively.
Employers can make a business case for expanding access to pharmacotherapy treatment for OUD based on our finding that receipt of pharmacotherapy significantly reduces overall health care costs.
测量阿片类药物使用障碍（OUD）的流行率，以及有无 OUD 时员工的医疗保健和生产力成本，并评估阿片类药物使用障碍的药物治疗的使用是否降低了这些成本。
我们使用 IBM MarketScan 数据库（密歇根州安阿伯）对 2016 年至 2017 年的商业参保、医疗保健和药房理赔以及健康风险评估数据进行了横断面分析。我们使用回归模型评估 OUD 与员工年度医疗保健和生产力成本之间的关联。
接受药物治疗和未接受药物治疗的 OUD 员工的医疗保健和生产力成本分别比其他员工高出约 6294 美元和 21570 美元。
根据我们的发现，接受药物治疗可显著降低整体医疗保健成本，雇主可以为扩大阿片类药物使用障碍药物治疗的获取提供商业案例。
